Compare Cassava Sciences Inc (FLNA) vs Reddit Inc (RDDT) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

RDDT trades at $160.63, up 5.14% over 24 hours, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability, with a net income margin of 31.35% and consecutive quarterly EPS beats. Recent news includes a partnership with Zefr for advertiser insights and a legal win against Anthropic, though concerns arise from the CEO's stock sale and the discontinuation of RSS feeds.

The outlook is positive, supported by robust earnings growth and a consensus price target of $202.52, implying significant upside. Key risks include competitive pressures in social media, potential regulatory scrutiny, and market volatility. Institutional ownership trends and analyst buy ratings (65.52%) reinforce a constructive view, but investors should monitor execution on growth initiatives.